Walder Wyss has advised BC Platforms, an expert of data science solutions for personalized healthcare, drug discovery and life science research, in connection with the CHF 20 million (approx. USD 20 million) growth financing round. This growth equity financing was led by new investor Jolt Capital, a fully independent private equity firm that specialises in growth capital deeptech investing in Europe.
The global leader in healthcare data management and analytics will use new financing to help accelerate the expansion of the company’s data footprint, consolidating the company’s position as the leading European data provider, and enabler of personalized precision medicine, with a focus on sourcing clinically valuable Real-World Data (RWD) from European and Asian countries. The goal is to provide users of BCP’s services, which include over ten of the world’s largest pharmaceutical companies, with over 100 million accessible subjects by 2026.
The financing will also accelerate the technology leadership of the company’s platform concerning data privacy, data harmonising functionalities and federated machine learning (AI) which can rapidly deliver powerful insights to life science researchers and clinicians.
The Walder Wyss team includes partner Alexander Gutmans (corporate/m&a and venture capital, pictured), Karina Tschon (associate, corporate/m&a and venture capital) and Lucas Maurer (associate, corporate/m&a and venture capital).